Craig Dees - Provectus Biopharmaceutica Chairman
PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Chairman
Dr. H. Craig Dees Ph.D. is the Chief executive officer and member of the board of Provectus Biopharmaceuticals Inc. since April 23 2002. Before joining us from 1997 to 2002 he served as senior member of the management team of Photogen Technologies Inc. including serving as a member of the board of directors of Photogen from 1997 to 2000. Prior to joining Photogen Dr. Dees served as a Group Leader at the Oak Ridge National Laboratory and as a senior member of the management teams of LipoGen Inc. a medical diagnostic company which used genetic engineering technologies to manufacture and distribute diagnostic assay kits for autoimmune diseases and TechAmerica Group Inc. now a part of Boehringer Ingelheim Vetmedica Inc. the U.S. animal health subsidiary of Boehringer Ingelheim GmbH an international chemical and pharmaceutical company headquartered in Germany. He earned a Ph.D. in Molecular Virology from the University of WisconsinMadison in 1984. since 2002.
Age | 62 |
Tenure | 22 years |
Phone | 866 594 5999 |
Web | https://www.provectusbio.com |
Provectus Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (1.8529) % which means that it has lost $1.8529 on every $100 spent on assets. This is way below average. Provectus Biopharmaceutica's management efficiency ratios could be used to measure how well Provectus Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 7 records | CHAIRMAN Age | ||
Keith Helming | AerCap Holdings NV | 56 | |
Paul Dacier | AerCap Holdings NV | 62 | |
Morry Rubin | FlexShopper | 54 | |
Shuang Chen | China Aircraft Leasing | 48 | |
Aengus Kelly | AerCap Holdings NV | 50 | |
Benjamin Silbermann | 41 | ||
Pieter Korteweg | AerCap Holdings NV | 77 |
Management Performance
Return On Asset | -1.85 |
Provectus Biopharmaceutica Leadership Team
Elected by the shareholders, the Provectus Biopharmaceutica's board of directors comprises two types of representatives: Provectus Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Provectus. The board's role is to monitor Provectus Biopharmaceutica's management team and ensure that shareholders' interests are well served. Provectus Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Provectus Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Pershing, Chairman of the Board | ||
Heather CPA, Chief Officer | ||
Alfred Smith, Independent Director | ||
Bruce Horowitz, COO Director | ||
John Glass, Interim CFO | ||
Eric Wachter, CTO and Executive VP | ||
Heather Raines, CFO | ||
Craig Dees, Chairman, CEO, CEO of Xantech and Director of Xantech | ||
Jan Koe, Independent Director | ||
Peter Culpepper, CFO, COO | ||
John Lacey, Director | ||
Timothy Scott, President, Director and President of Xantech and Director of Xantech | ||
Dominic Rodrigues, Chairman of the Board | ||
Kelly McMasters, Independent Director | ||
Marlon Nurse, IR Contact Officer |
Provectus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Provectus Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -1.85 | ||||
Operating Margin | (4.77) % | ||||
Current Valuation | 46.73 M | ||||
Shares Outstanding | 419.55 M | ||||
Shares Owned By Insiders | 3.69 % | ||||
Shares Owned By Institutions | 0.04 % | ||||
Number Of Shares Shorted | 1.82 M | ||||
Price To Earning | (0.48) X | ||||
Price To Book | 5.44 X | ||||
Price To Sales | 55.94 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Provectus Biopharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Provectus Biopharmaceutica's short interest history, or implied volatility extrapolated from Provectus Biopharmaceutica options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Provectus Biopharmaceutica using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |